DGMT - Tao Chen E07796 possible CDER funding Sequencing contract
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- NCTR Acquisition Liaison nctracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) within the Department of Health and Human Services is seeking a contractor to provide sequencing services under possible CDER (Center for Drug Evaluation and Research) funding as part of the DGMT - Tao Chen E07796 initiative. This new requirement focuses on research and development in biotechnology, specifically excluding nanobiotechnology applications. The solicitation is estimated to be released on February 1, 2026, with an anticipated award date of April 1, 2026.
The estimated contract award value ranges from $25,000 to $250,000, reflecting a flexible budget range to accommodate various scope scenarios. No small business set-aside restrictions apply to this opportunity, allowing all eligible contractors to compete. Interested parties should direct inquiries to the FDA's Acquisition Liaison team at nctracquisitions@fda.hhs.gov for additional information regarding this biotechnology research and development contract.
Forecast text
DGMT - Tao Chen E07796 possible CDER funding Sequencing contract
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast